|
| Press Releases |
|
 |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
| Monday, January 18, 2021 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
| Monday, November 23, 2020 |
|
|
SinoMab Commenced Construction of its China Headquarters |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, July 23, 2020 |
|
|
SinoMab entered into Strategic Collaboration with D2M |
| SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, June 10, 2020 |
|
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Wednesday, October 30, 2019 |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Prime Minister Paetongtarn Positions Thailand as Regional AI Ethics Leader: Official Launch of AIGPC at the UNESCO Global Forum on the Ethics of AI 2025 
Jun 27, 2025 17:00 HKT/SGT
|
|
|
GA-ASI Announces Investment in Dutch Technology Innovator Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
IBI Announces 23-Fold Surge in Net Profit for FY2025
Jun 26, 2025 22:37 HKT/SGT
|
|
|
Wasion Wins Three Major Smart Power Meter Contracts In Emerging Overseas Markets, Total Contract Value Exceeds HK$940 million
Jun 26, 2025 20:58 HKT/SGT
|
|
|
AEON Credit Reported Rebound Growth in 1QFY2025/26, Net Profit Up 31.3% to HK$109.3 million
Jun 26, 2025 20:01 HKT/SGT
|
|
|
Regina Miracle FY25 Net Profit Up by 28.4% to HK$180 Million
Jun 26, 2025 19:19 HKT/SGT
|
|
|
On Its Centennial: The Occasion of Replacing the Kiswa of the Noble Kaaba Embodies the Kingdom of Saudi Arabia's Enduring Care for the Two Holy Mosques
Jun 26, 2025 15:00 HKT/SGT
|
|
|
World's Premier AI Conference, World AI Show - Indonesia 2025, Arrives in Jakarta to Power Southeast Asia's AI Revolution
Jun 26, 2025 12:31 HKT/SGT
|
|
|
Honda Opens "Honda Software Studio Osaka" as New Software Development Operation
Jun 26, 2025 13:30 JST
|
|
|
Honda Issues "Honda ESG Report 2025"
Jun 26, 2025 13:29 JST
|
|
|
Fujitsu's Uvance Wayfinders consulting empowers customers to evolve business foundations leveraging data and AI
Jun 26, 2025 11:00 JST
|
|
|
XCF Global and Continual Renewable Ventures Announce Memorandum of Understanding to Launch New Rise Australia, a SAF and HVO Platform Powered by XCF
Jun 26, 2025 09:30 HKT/SGT
|
|
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 21:27 HKT/SGT
|
|
|
Galaxy Payroll Partners with CURRENC to Integrate AI and Stablecoin Technology in HR Solutions
Jun 25, 2025 20:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
